Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission

Vaccine

Volumn 34, Issue 5, 2016, Pages 616-621

  Orellano, Pablo Wenceslao ^a,b   Reynoso, Julieta Itati ^c   Stahl, Hans Christian ^d   Salomon, Oscar Daniel ^a,e  

^a Consejo Nacional de Investigaciones Cientificas y Tecnicas ^*  (Argentina)

^b UNIVERSIDAD TECNOLÓGICA NACIONAL   (Argentina)

^c Hospital Interzonal General de Agudos San Felipe   (Argentina)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Instituto Nacional de Medicina Tropical ^*  (Argentina)

Author keywords

Argentina; Cost utility analysis; Dengue; Dengue vaccines

Indexed keywords

DENGUE VACCINE;

ARGENTINA; ARTICLE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DENGUE; DISABILITY ADJUSTED LIFE YEAR; DISEASE TRANSMISSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TASK PERFORMANCE; VACCINATION; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; MARKOV CHAIN; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RISK;

ARGENTINA; COST-BENEFIT ANALYSIS; DENGUE; HUMANS; IMMUNIZATION PROGRAMS; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RISK; VACCINATION;

EID: 84953807126     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.040     Document Type: Article

References (43)

1. Bouzid M., Colón-González F.J., Lung T., Lake I.R., Hunter P.R. Climate change and the emergence of vector-borne diseases in Europe: case study of dengue fever. BMC Public Health 2014, 14(1):781. 10.1186/1471-2458-14-781.
2. World Health Organization. Dengue and severe dengue fact sheet N°117. Available at. Updated May 2015. http://www.who.int/mediacentre/factsheets/fs117/en/.
3. Vezzani D., Carbajo A.E. Aedes aegypti Aedes albopictus, and dengue in Argentina: current knowledge and future directions. Mem Inst Oswaldo Cruz 2008, 103(1):66-74.
4. Zambrini D.A. Neglected lessons from the 2009 dengue epidemic in Argentina. Rev Saude Publica 2011, 45(2):428-431.
5. Thisyakorn U., Thisyakorn C. Latest developments and future directions in dengue vaccines. Ther Adv Vaccines 2014, 2(1):3-9. 10.1177/2051013613507862.
6. Ishikawa T., Yamanaka A., Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 2014, 32(12):1326-1337. 10.1016/j.vaccine.2014.01.040.
7. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 10.1016/S0140-6736(14)61060-6.
8. Villar L., Dayan G.H., Arredondo-García J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372(2):113-123. 10.1056/NEJMoa1411037.
9. Hadinegoro S.R., Arredondo-García J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015, [Epub ahead of print].
10. Wilder-Smith A. Dengue vaccines: dawning at last?. Lancet 2014, 10.1016/S0140-6736(14)61142-9.
11. Sinha G. Sanofi's dengue vaccine first to complete phase 3. Nat Biotechnol 2014, 32(7):605-606. 10.1038/nbt0714-605a.
12. Shepard D.S., Suaya J.A., Halstead S.B., Nathan M.B., Gubler D.J., Mahoney R.T., et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 2004, 22(9-10):1275-1280.
13. Lee B.Y., Connor D.L., Kitchen S.B., Bacon K.M., Shah M., Brown S.T., et al. Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg 2011, 84(5):764-772. 10.4269/ajtmh.2011.10-0624.
14. Carrasco L.R., Lee L.K., Lee V.J., Ooi E.E., Shepard D.S., Thein T.L., et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis 2011, 5(12):e1426. 10.1371/journal.pntd.0001426.
15. Durham D.P., Ndeffo Mbah M.L., Medlock J., Luz P.M., Meyers L.A., Paltiel A.D., et al. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31(37):3957-3961. 10.1016/j.vaccine.2013.06.036.
16. Husereau D., Drummond M., Petrou S., Carswell C., Moher D., Greenberg D., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013, 346:f1049. 10.1136/bmj.f1049.
17. Amaku M., Coudeville L., Massad E. Designing a vaccination strategy against dengue. Rev Inst Med Trop Sao Paulo 2012, 54(Suppl. 18):S18-S21.
18. Pan American Health Organization. Dengue Regional Information: Number of Cases. Available at . http://www.paho.org/hq/index.php?option=com_topics%26view=article%26id=1%26Itemid=40734%26lang=en.
19. Thai K.T., Nishiura H., Hoang P.L., Tran N.T., Phan G.T., Le H.Q., et al. Age-specificity of clinical dengue during primary and secondary infections. PLoS Negl Trop Dis 2011, 5(6):e1180. 10.1371/journal.pntd.0001180.
20. Gentile Á., Bakir J., Firpo V., Caruso M., Lución M.F., Abate H.J., et al. Delayed vaccine schedule and missed opportunities for vaccination in children up to 24 months. A multicenter study. Arch Argent Pediatr 2011, 109(3):219-225. 10.1590/S0325-00752011000300006.
21. Ciudad Autónoma de Buenos Aires. Anexo del boletín oficial N° 4354. Available at . http://boletinoficial.buenosaires.gob.ar/documentos/boletines/2014/03/20140310ax.pdf.
22. Krol M., Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014, 32(4):335-344. 10.1007/s40273-014-0132-3.
23. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567. 10.1016/S0140-6736(12)61428-7.
24. Mahoney R.T., Francis D.P., Frazatti-Gallina N.M., Precioso A.R., Raw I., Watler P., et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012, 30(32):4892-4896. 10.1016/j.vaccine.2012.02.064.
25. da Costa V.G., Marques-Silva A.C., Floriano V.G., Moreli M.L. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. Vaccine 2014, 32(39):4885-4892. 10.1016/j.vaccine.2014.07.008.
26. World Health Organization. Global burden of disease 2004 update: disability weights for diseases and conditions. Available at . http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf.
27. Muening P. Cost-effectiveness analysis in health, a practical approach 2008, Jossey-Bass, San Francisco. 2nd ed.
28. World Health Organization World health report 2002: reducing risks, promoting healthy life 2002, World Health Organization, Geneva.
29. International Monitory Fund. The World Economic Outlook (WEO) database. GDP per capita (current US$). Available at . http://www.imf.org/external/pubs/ft/weo/2015/01/weodata/index.aspx.
30. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(42):7229-7241. 10.1016/j.vaccine.2011.06.094.
31. Thomas S.J. Preventing dengue - is the possibility now a reality?. N Engl J Med 2015, 372(2):172-173. 10.1056/NEJMe1413146.
32. Arnold R.J. Pharmacoeconomics: 1. From theory to practice 2010, CRC Press, Boca Raton.
33. Seijo A. Dengue 2009: chronology of an epidemic. Arch Argent Pediatr 2009, 107(5):387-389. 10.1590/S0325-00752009000500002.
34. Johansson M.A., Hombach J., Cummings D.A. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine 2011, 29(35):5860-5868. 10.1016/j.vaccine.2011.06.042.
35. Van Vlaenderen I., Van Bellinghen L.A., Meier G., Nautrup B.P. An approximation of herd effect due to vaccinating children against seasonal influenza - a potential solution to the incorporation of indirect effects into static models. BMC Infect Dis 2013, 13:25. 10.1186/1471-2334-13-25.
36. Martí S.G., Colantonio L., Bardach A., Galante J., Lopez A., Caporale J., et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc 2013, 11(1):21. 10.1186/1478-7547-11-21.
37. Bärnighausen T., Bloom D.E., Cafiero E.T., O'Brien J.C. Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Semin Immunol 2013, 25(2):104-113. 10.1016/j.smim.2013.04.010.
38. Grange L., Simon-Loriere E., Sakuntabhai A., Gresh L., Paul R., Harris E. Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol 2014, 5:280. 10.3389/fimmu.2014.00280.
39. Sabchareon A., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., Jiwariyavej V., et al. Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009. PLoS Negl Trop Dis 2012, 6(7):e1732. 10.1371/journal.pntd.0001732.
40. Trung D.T., Thao le T.T., Dung N.M., Ngoc T.V., Hien T.T., Chau N.V., et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop Dis 2012, 6(6):e1679. 10.1371/journal.pntd.0001679.
41. Guilarde A.O., Turchi M.D., Siqueira J.B., Feres V.C., Rocha B., Levi J.E., et al. Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. J Infect Dis 2008, 197(6):817-824. 10.1086/528805.
42. Suaya J.A., Shepard D.S., Siqueira J.B., Martelli C.T., Lum L.C., Tan L.H., et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009, 80(5):846-855.
43. Anderson K.B., Chunsuttiwat S., Nisalak A., Mammen M.P., Libraty D.H., Rothman A.L., et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007, 369A(9571):1452-1459.